FDA grants breakthrough therapy designation to Merck’s MK-6482 in VHL disease-associated RCC

This article was originally published here

The FDA also granted orphan drug designation to MK-6482 for VHL disease. These designations are based on data from a Phase 2 trial evaluating MK-6482 in patients with

The post FDA grants breakthrough therapy designation to Merck’s MK-6482 in VHL disease-associated RCC appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply